Alembic Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Alembic Ltd’s record carries a multi-year consolidated audit qualification, a promoter family that holds every key role while drawing escalating pay that public institutions vote against unanimously, and a ₹250 crore inter-corporate deposit to a wholly owned subsidiary carrying 1% interest. The core business generates cash, but the cash is routinely paid out in dividends that outrun free cash flow, and the revenue book shows rising customer concentration alongside a sharp decline in contract liabilities.

Key findings

  1. A ₹1,025.66 crore reserve transfer at an associate drew a multi-year audit qualification Major - Associate Alembic Pharmaceuticals Limited transferred ₹1,025.66 crore from General Reserve to profit under “Exceptional Items” in FY2022-23, and its independent auditor qualified the opinion because the transfer did not meet the definition of income under Ind AS. That qualification carried forward into Alembic Ltd’s consolidated audit opinion for FY2023-24, solely on the comparability impact of the prior-year entry. Separately, the Group has used government registration rates instead of Registered Valuer reports for investment property fair values from FY2020-21 through FY2024-25.
  2. A promoter family holds all key roles, and the son’s commission draws institutional opposition Major - Mr. Chirayu Amin (Chairman), Mrs. Malika Amin (MD & CEO until 1 January 2026), and Mr. Udit Amin (Non-Executive Director until 30 September 2025, then Managing Director) are husband, wife, and son, holding the three promoter-director positions continuously from FY2019 through FY2026. Mr. Udit Amin’s commission rose from ₹1.25 crore in FY2020 to ₹3.00 crore in FY2025, each year requiring a special resolution because his pay alone exceeded half of all non-executive director remuneration. At the FY2024 and FY2025 AGMs, public institutional shareholders voted 100% against the commission resolution; at the FY2023 AGM, they voted 12.76% against.
  3. RPT limits far exceed actual use, and a ₹250 crore inter-corporate deposit carries 1% interest Major - Shareholder approvals for material related party transactions with Shreno Limited set a ₹30 crore annual limit while actual transactions ranged from ₹5.63 crore to ₹12.45 crore across FY2023-FY2025. The Shreno limit represented 23.58% of Alembic Ltd’s consolidated turnover at the time of approval. A ₹250 crore inter-corporate deposit to wholly owned subsidiary Alembic City Limited carried an interest rate of 1% per annum with a maximum tenure of 10 years as at 28 November 2022.
  4. Revenue quality is pressured by customer concentration and a decline in contract liabilities Minor - The API segment’s single largest customer contributed ₹43.23 crore of revenue in FY26, up from ₹26.45 crore in FY25. Contract liabilities fell 41% to ₹21.68 crore from ₹36.91 crore a year earlier.
  5. Dividends consistently outstrip free cash flow Minor - Operating cash flow recovered to ₹120 crore in FY26 against a profit of ₹126 crore, after FY24 saw just ₹22.69 crore of cash flow on ₹92.87 crore of profit. The ₹61 crore dividend in FY26 consumed 141% of free cash flow of ₹43 crore. Standalone capital work-in-progress stood at ₹150.21 lakh with no projects suspended or overrunning cost in any year from FY22 through FY26.

What to watch

Bottom line: This is a disclosed record with a genuine cash-generating business, but the governance structure concentrates every key role in one promoter family whose pay escalates against unanimous institutional opposition. The consolidated audit opinion has carried a qualification for two years running because of an associate’s accounting choice, and a ₹250 crore inter-corporate deposit to a wholly owned subsidiary carries only 1% interest. Watch the AGM vote and the court ruling.